

Table 21.15
Cancer of the Ovary (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2014
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 ^e	0 to <39 ^e	>=39 ^g	Complete ^h
<u>Race</u>										
All Races ^b	70,057	38,021	27,971	22,155	18,338	14,216	173,433	207,303	14,757	222,060
White ^b	60,367	32,857	24,544	19,599	16,416	12,771	150,987	181,274	12,476	193,750
Black ^b	5,474	2,614	1,678	1,368	1,148	979	12,095	14,446	1,518	15,964
Asian/Pacific Islander ^c	3,247	2,007	1,394	863	+	+	7,819	+	+	+
Hispanic ^d	7,171	3,477	2,312	1,679	+	+	15,172	+	+	+

Estimated prevalence percent^a on January 1, 2014, of the SEER^c population diagnosed in the previous 22 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^f
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races ^c	0.0988%	0.0004%	0.0061%	0.0196%	0.0351%	0.0799%	0.1725%	0.2680%	0.3131%	0.2519%	0.0865%
White ^c	0.1098%	0.0004%	0.0060%	0.0209%	0.0368%	0.0815%	0.1828%	0.2925%	0.3473%	0.2744%	0.0929%
Black ^c	0.0528%	-	0.0051%	0.0143%	0.0280%	0.0580%	0.0968%	0.1511%	0.1873%	0.1595%	0.0538%
Asian/Pacific Islander ^c	0.0853%	-	0.0068%	0.0187%	0.0332%	0.0885%	0.1787%	0.2188%	0.2099%	0.1659%	0.0757%
Hispanic ^d	0.0578%	-	0.0080%	0.0239%	0.0370%	0.0665%	0.1309%	0.2263%	0.2478%	0.2109%	0.0731%

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^b US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.

^c Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

^d Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

^e Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^g (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.